PT3986401T - Composto peptidomimético (r)-2-amino-n-((s)-l-(((s)-5- amino-l-(3-benzil-1,2,4-oxadiazol-5-il)pentil)amino)-3-(4- hidroxi-2,6-dimetilfenil)-1-oxopropan-2-il)-5- guanidinopentanamida no tratamento de doenças neurodegenerativas - Google Patents

Composto peptidomimético (r)-2-amino-n-((s)-l-(((s)-5- amino-l-(3-benzil-1,2,4-oxadiazol-5-il)pentil)amino)-3-(4- hidroxi-2,6-dimetilfenil)-1-oxopropan-2-il)-5- guanidinopentanamida no tratamento de doenças neurodegenerativas

Info

Publication number
PT3986401T
PT3986401T PT207545070T PT20754507T PT3986401T PT 3986401 T PT3986401 T PT 3986401T PT 207545070 T PT207545070 T PT 207545070T PT 20754507 T PT20754507 T PT 20754507T PT 3986401 T PT3986401 T PT 3986401T
Authority
PT
Portugal
Prior art keywords
amino
guanidinopentanamide
oxopropan
oxadiazol
dimethylphenyl
Prior art date
Application number
PT207545070T
Other languages
English (en)
Original Assignee
Stealth Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Inc filed Critical Stealth Biotherapeutics Inc
Publication of PT3986401T publication Critical patent/PT3986401T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PT207545070T 2019-07-24 2020-07-23 Composto peptidomimético (r)-2-amino-n-((s)-l-(((s)-5- amino-l-(3-benzil-1,2,4-oxadiazol-5-il)pentil)amino)-3-(4- hidroxi-2,6-dimetilfenil)-1-oxopropan-2-il)-5- guanidinopentanamida no tratamento de doenças neurodegenerativas PT3986401T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878272P 2019-07-24 2019-07-24
US202063046292P 2020-06-30 2020-06-30

Publications (1)

Publication Number Publication Date
PT3986401T true PT3986401T (pt) 2026-02-03

Family

ID=72047083

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207545070T PT3986401T (pt) 2019-07-24 2020-07-23 Composto peptidomimético (r)-2-amino-n-((s)-l-(((s)-5- amino-l-(3-benzil-1,2,4-oxadiazol-5-il)pentil)amino)-3-(4- hidroxi-2,6-dimetilfenil)-1-oxopropan-2-il)-5- guanidinopentanamida no tratamento de doenças neurodegenerativas

Country Status (13)

Country Link
US (3) US11273149B2 (pt)
EP (1) EP3986401B1 (pt)
JP (2) JP7638265B2 (pt)
KR (1) KR20220041118A (pt)
CN (1) CN114466656A (pt)
AU (1) AU2020316449B2 (pt)
BR (1) BR112022001123A2 (pt)
CA (1) CA3148090A1 (pt)
DK (1) DK3986401T3 (pt)
FI (1) FI3986401T3 (pt)
IL (1) IL289874A (pt)
PT (1) PT3986401T (pt)
WO (1) WO2021016462A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022370358A1 (en) * 2021-10-20 2024-05-02 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023133321A1 (en) 2022-01-10 2023-07-13 Stealth Biotherapeutics Inc. Small molecule peptidomimetic for the treatment of tauopathies
EP4525840A1 (en) * 2022-05-18 2025-03-26 Stealth BioTherapeutics Inc. Compositions and methods for the treatment of huntington's disease and htt proteinopathies
AU2023367200A1 (en) * 2022-10-26 2025-05-08 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of neurodegenerative disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ES2559859T3 (es) * 2007-05-16 2016-02-16 The Brigham And Women's Hospital, Inc. Tratamiento de sinucleinopatías
CN106620645A (zh) 2010-07-09 2017-05-10 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
US9375597B2 (en) 2012-05-10 2016-06-28 Sidney Ralph Barker Upper body toning device
US9617309B2 (en) 2012-09-26 2017-04-11 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
EP4000690A1 (en) * 2016-05-19 2022-05-25 Stealth BioTherapeutics Inc. Compositions and methods for the prevention and treatment of mitochondrial myopathies
WO2018034901A1 (en) 2016-08-16 2018-02-22 Stealth Biotherapeutics N-carboxyanhydride-based-scale synthesis of elamipretide
US20210172963A1 (en) * 2017-05-26 2021-06-10 University Of Miami Determining onset of amyotrophic lateral sclerosis
CN117624286A (zh) * 2017-12-15 2024-03-01 隐形生物治疗公司 线粒体靶向肽

Also Published As

Publication number Publication date
JP7638265B2 (ja) 2025-03-03
US12016843B2 (en) 2024-06-25
AU2020316449A1 (en) 2022-02-10
AU2020316449B2 (en) 2026-02-05
DK3986401T3 (da) 2026-02-23
CN114466656A (zh) 2022-05-10
EP3986401B1 (en) 2026-01-28
US11273149B2 (en) 2022-03-15
BR112022001123A2 (pt) 2022-03-15
KR20220041118A (ko) 2022-03-31
FI3986401T3 (fi) 2026-03-17
JP2022542882A (ja) 2022-10-07
AU2020316449A8 (en) 2022-02-17
IL289874A (en) 2022-03-01
EP3986401A1 (en) 2022-04-27
US20220265615A1 (en) 2022-08-25
US20250009717A1 (en) 2025-01-09
JP2025097980A (ja) 2025-07-01
WO2021016462A1 (en) 2021-01-28
US20210023062A1 (en) 2021-01-28
CA3148090A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
PT3986401T (pt) Composto peptidomimético (r)-2-amino-n-((s)-l-(((s)-5- amino-l-(3-benzil-1,2,4-oxadiazol-5-il)pentil)amino)-3-(4- hidroxi-2,6-dimetilfenil)-1-oxopropan-2-il)-5- guanidinopentanamida no tratamento de doenças neurodegenerativas
EA201991515A1 (ru) N-[4-фтор-5-[[(2s,4s)-2-метил-4-[(5-метил-1,2,4-оксадиазол-3-ил)метокси]-1-пиперидил]метил]тиазол-2-ил]ацетамид в качестве ингибитора oga
EA202193015A1 (ru) Ингибиторы cdk
EA202193007A1 (ru) Соединения пирролидина
EA201001532A1 (ru) Соединения фенилзамещенного 2-имино-3-метилпирролопиримидинона в качестве ингибиторов bace-1, композиции и их применение
MX346186B (es) Inhibidores de proteina cinasas.
EA201790838A1 (ru) Ингибитор киназы aurora a
EP4674481A3 (en) Cd73 inhibitors
JOP20180094A1 (ar) مركب حلقي غير متجانس كمثبط بروتين كيناز
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
PL3974441T3 (pl) Związek peptydowy lub jego farmaceutycznie dopuszczalna sól
EA202190532A1 (ru) Ингибиторы аргиназы и способы их применения
MX2021005740A (es) Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo.
EA202192193A1 (ru) Комбинации бета-лактамных соединений и пробенецида и их применения
PH12021552349A1 (en) Biomarkers for selinexor
JOP20200133A1 (ar) طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
EA202190359A1 (ru) Способы лечения нейродегенеративных расстройств
EA201892382A1 (ru) Замещенные бициклические гетероциклические соединения
SA522431572B1 (ar) مركب بيريميدين-5-كربوكساميد
EP4217355A4 (en) AGENTS FOR TREATING DISEASES BY INHIBITING FOXO1
EP4069693C0 (en) HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP4011394A4 (en) METHODS OF TREATMENT OF ALZHEIMER'S DISEASE BY INHIBITING THE UPtake OF AMINO ACIDS BY T-CELLS